Skip to main content
SpringerLink
Log in

Recombinant Hepatitis B Vaccine

A Review of its Immunogenicity and Protective Efficacy Against Hepatitis B

  • Adis Drug Evaluation
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Recombinant hepatitis B vaccine Engerix B® [Hep-B (Eng)] is a noninfectious subunit hepatitis B viral vaccine indicated for the active immunisation of adults, children and infants against hepatitis B virus infection. It contains hepatitis B surface antigen (HBsAg) which is produced by the yeast Saccharomyces cerevisiae by use of recombinant DNA technology.

In adults and children seroprotection rates [anti-HBsAg antibody (anti-HBs) titres ≥10 IU/L] were 93 to 100% 1 month after completion of the immunisation schedule with Hep-B (Eng) [0, 1, 6-month schedule]. A more rapid immunological response has been reported with accelerated Hep-B (Eng) immunisation schedules, such as the 0, 1, 2, 12-month schedule. Hep-B(Eng) produces seroprotection rates similar to those achieved with the plasma-derived vaccines and the recombinant hepatitis B vaccine, Recombivax-HB® [Hep-B (Rax)] when administered at recommended doses.

In studies in Taiwanese and Thai neonates born to hepatitis B carrier mothers, seroprotection rates were ≥94% 12 months after immunisation with Hep-B (Eng) [± hepatitis B immunoglobulin (HBIG)] and protective efficacy was high, with ≤4% of neonates becoming chronic hepatitis B carriers. Similarly, among 119 homosexual men, none had any markers of hepatitis B infection 1 month after completion of immunisation with Hep-B (Eng). Immunoprophylaxis with Hep-B(Eng) ± HBIG compared with no immunoprophylaxis also resulted in a lower incidence of acute symptomatic hepatitis B infection among healthcare workers accidentally exposed to HBsAg-positive blood (0 vs 6%).

Although seroprotective levels of anti-HBs have been reported to persist for at least 5 years in adults and 8 years in children immunised with Hep-B (Eng), anti-HBs titres do decline with time and may become undetectable several years after immunisation in some vaccinees. Moreover, it is currently unclear whether vaccinees require booster doses or whether, on exposure to the virus, natural boosting occurs when anti-HBs titres fall below the protective level (<10 IU/L). Long term follow-up studies should clarify this issue.

Hep-B(Eng) is generally well tolerated with a tolerability profile similar to that of Hep-B(Rax) and plasma-derived vaccines. Mild soreness at the injection site is the most common adverse event associated with Hep-B(Eng).

Conclusions: Although further long term follow-up is necessary to determine the persistence of protective immunity against hepatitis B, available data indicate that Hep-B (Eng) is an effective and suitable alternative to other vaccines currently used for immunisation against infection caused by hepatitis B virus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lee WM. Hepatitis B viras infection. N Engl J Med 1997 Dec 11; 337(24): 1733–45

    PubMed  CAS  Google Scholar 

  2. Leroux-Roels G, Desombre I, De Tollenaere G, et al. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults. Vaccine 1997; 15(16): 1724–31

    PubMed  CAS  Google Scholar 

  3. Iwarson S. New approaches to hepatitis A and B vaccines. APMIS 1995 May; 103: 321–6

    PubMed  CAS  Google Scholar 

  4. Robinson WS. Hepadnaviridae. Hepatitis B viras and hepatitis D virus. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s principles and practice of infectious diseases. 4th ed. v. 2. New York: Churchill Living-stone, 1995: 1406–39

    Google Scholar 

  5. Hall AJ. Hepatitis in travellers: epidemiology and prevention. Br Med Bull 1993 Apr; 49: 382–93

    PubMed  CAS  Google Scholar 

  6. Garrison MW, Baker DE. Therapeutic advances in the prevention of hepatitis B: yeast-derived recombinant hepatitis B vaccines. DICP 1991 Jun; 25: 617–27

    PubMed  CAS  Google Scholar 

  7. Thompson SC, Ruff TA. Hepatitis B vaccination: what are the current international recommendations? Clin Immunother 1995 Jan; 3: 15–26

    Google Scholar 

  8. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336(3): 196–204

    PubMed  CAS  Google Scholar 

  9. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995; 13Suppl. 1: S47–9

    PubMed  Google Scholar 

  10. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991; 11(2): 84–92

    PubMed  CAS  Google Scholar 

  11. Deinhardt F, Zuckerman AJ. Immunization against hepatitis B: report on a WHO meeting on viral hepatitis in Europe. J Med Virol 1985; 17: 209–17

    PubMed  CAS  Google Scholar 

  12. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996 Aug; 14: 1019–27

    PubMed  CAS  Google Scholar 

  13. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989 Sep 4; 87Suppl. 3A: 36S–40S

    PubMed  CAS  Google Scholar 

  14. Wiström J. Intramuscular vs intradermal hepatitis B vaccination: a 6-year follow-up [letter]. J Am Med Assoc 1995 Jun 21; 273(23): 1835–6

    Google Scholar 

  15. Struve J, Aronsson B, Frenning B, et al. Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response. Scand J Infect Dis 1992; 24: 423–9

    PubMed  CAS  Google Scholar 

  16. Payton CD, Scarisbrick DA, Sikotra S, et al. Vaccination against hepatitis B: comparison of intradermal and intramuscular administration of plasma derived and recombinant vaccines. Epidemiol Infect 1993; 110(1): 177–80

    PubMed  CAS  Google Scholar 

  17. González ML, Usandizaga M, Alomar P, et al. intradermal and intramuscular route for vaccination against hepatitis B. Vaccine 1990 Aug; 8: 402–5

    PubMed  Google Scholar 

  18. Morris CA, Oliver PR, Reynolds F, et al. Intradermal hepatitis B immunization with yeast-derived vaccine: serological response by sex and age. Epidemiol Infect 1989; 103(2): 387–94

    PubMed  CAS  Google Scholar 

  19. Harries AD, Clark M, Beeching NJ, et al. Early anti-HBs antibody response to accelerated and to conventional hepatitis B vaccination regimens in healthy persons. J Infect 1991; 23(3): 251–4

    PubMed  CAS  Google Scholar 

  20. Zanetti AR, Tanzi E, Pozzi A, et al. Yeast-derived hepatitis B vaccine in dental students. A three-year follow-up study. Vaccine 1990 Jun; 8(3): 205–8

    PubMed  CAS  Google Scholar 

  21. Hess G, Hingst V, Cseke J, et al. Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination. Eur J Clin Microbiol Infect Dis 1992; 11(4): 334–40

    PubMed  CAS  Google Scholar 

  22. Marsano LS, Greenberg RN, Kirkpatrick RB, et al. Comparison of a rapid hepatitis B immunization schedule to the standard schedule for adults. Am J Gastroenterol 1996; 91(1): 111–5

    PubMed  CAS  Google Scholar 

  23. Dahl-Hansen E, Siebke JC, Froland SS, et al. Immunogenicity of yeast-derived hepatitis B vaccine from two different producers. Epidemiol Infect 1990; 104: 143–9

    PubMed  CAS  Google Scholar 

  24. Bock HL, Kruppenbacher J, Sänger R, et al. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med 1996 Oct 28; 156(19): 2226–31

    PubMed  CAS  Google Scholar 

  25. Scheiermann N, Gesemann M, Maurer C, et al. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules. Vaccine 1990; 8 Suppl.: S44–6

    PubMed  Google Scholar 

  26. Palmovic D, Crnjakovic-Palmovic J. Vaccination against hepatitis B: results of the analysis of 2000 population members in Croatia. Eur J Epidemiol 1994; 10(5): 541–7

    PubMed  CAS  Google Scholar 

  27. Goudeau A, Denis F, Mounier M, et al. Comparative multicentre study of the immunogenicity of different hepatitis B vaccines in healthy volunteers. Postgrad Med J 1987; 63Suppl. 2: 125–8

    PubMed  Google Scholar 

  28. Chiaramonte M, Majori S, Ngatchu T, et al. Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity. Vaccine 1996; 14(2): 135–7

    PubMed  CAS  Google Scholar 

  29. Rogan PD, Duguid JKM. Immunisation of staff of a regional blood transfusion centre with a recombinant hepatitis B vaccine. J Infect 1991; 22(1): 5–9

    PubMed  CAS  Google Scholar 

  30. Bock HL, Löscher T, Scheiermann N, et al. Accelerated schedule for hepatitis B immunization. J Travel Med 1995; 2(4): 213–7

    PubMed  Google Scholar 

  31. Goldfarb J, Baley J, Vanderbrug Medendorp S, et al. Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B® hepatitis B vaccine in neonates. Pediatr Infect Dis J 1994 Jan; 13(1): 18–22

    PubMed  CAS  Google Scholar 

  32. Chirico G, Belloni C, Gasparoni A, et al. Hepatitis B immunization in infants of hepatitis B surface antigen-negative mothers. Pediatrics 1993; 92(5): 717–9

    PubMed  CAS  Google Scholar 

  33. Orsolini P, Belloni C, Klersy C, et al. Anti-HBV neonatal immunization with recombinant vaccine. Part I. Critical appraisal for a long-lived antibody course. Vaccine 1995; 13(6): 551–4

    PubMed  CAS  Google Scholar 

  34. Gunn TR, Woodfield DG. The persistence of anti-hepatitis B surface antibodies to three years of age: is a hepatitis B vaccine booster required? New Zealand Med J 1993 Nov 24; 106(968): 499–501

    PubMed  CAS  Google Scholar 

  35. Goldfarb J, Vanderbrug Medendorp SV, Garcia H, et al. Comparison study of the immunogenicity and safety of 5- and 10-μg dosages of a recombinant hepatitis B vaccine in healthy infants. Pediatr Infect Dis J 1996; 15(9): 764–7

    PubMed  CAS  Google Scholar 

  36. del Canho R, Grosheide PM, Voogd M, et al. Immunogenicity of 20 μg of recombinant DNA hepatitis-B vaccine in healthy neonates: a comparison of three different vaccination schemes. J Med Virol 1993; 41: 30–4

    PubMed  Google Scholar 

  37. Lau Y-L, Tam AYC, Ng KW, et al. Response of preterm infants to hepatitis B vaccine. J Pediatr 1992; 121(6): 962–5

    PubMed  CAS  Google Scholar 

  38. Chawareewong S, Jirapongsa A, Lokaphadhana K. Immune response to hepatitis B vaccine in premature neonates. Southeast Asian J Trop Med Public Health 1991; 22(1): 39–40

    PubMed  CAS  Google Scholar 

  39. Belloni C, Chirico G, Pistorio A, et al. Immunogenicity of hepatitis B vaccine in term and preterm infants. Acta Paediatr 1998; 87: 336–8

    PubMed  CAS  Google Scholar 

  40. Lee P-I, Lee C-Y, Huang L-M, et al. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 1995 May; 126:716–21

    PubMed  CAS  Google Scholar 

  41. Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, et al. Long term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch Dis Child 1997; 77: F47–51

    CAS  Google Scholar 

  42. Goldfarb J, Vanderbrug Medendorp SV, Nagamori K, et al. Comparison study of the immunogenicity and safety of 5- and 10-μg dosages of a recombinant hepatitis B vaccine in healthy children. Pediatr Infect Dis J 1996; 15(9): 768–71

    PubMed  CAS  Google Scholar 

  43. Milne A, Heydon JL, Hindle RC, et al. Prevalence of hepatitis B in children in a high risk New Zealand community, and control using recombinant DNA vaccine. N ZMed J 1989 Apr 26; 102: 182–4

    CAS  Google Scholar 

  44. Schiff GM, Sherwood JR, Zeldis JB, et al. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health 1995; 16(1): 12–7

    PubMed  CAS  Google Scholar 

  45. Poovorawan Y, Pongpunlert W, Theamboonlers A, et al. Randomized, single-blind comparison of the immunogenicity and reactogenicity of 20μg and 10μg doses of hepatitis B vaccine in adolescents. Southeast Asian J Trop Med Public Health 1993 Jun; 24(2): 255–9

    PubMed  CAS  Google Scholar 

  46. Miñana JS, Ganuza MG, Millán PF, et al. Hepatitis B vaccine immunoresponsiveness in adolescents: a revaccination proposal after primary vaccination. Vaccine 1996; 14(2): 103–6

    Google Scholar 

  47. Dobson S, Scheifele D, Bell A. Assessment of a universal, school-based hepatitis B vaccination program. JAMA 1995; 274(15): 1209–13

    PubMed  CAS  Google Scholar 

  48. Manyike PT, Aspinall S, Summers RS. Immunogenicity of recombinant hepatitis B vaccine in urban black children from Ga-Rankuwa, Bophuthatswana, South Africa. Pediatr Infect Dis J 1992 Sep; 11(9): 726–30

    CAS  Google Scholar 

  49. Wilkinson SE, Morath M, Bennett DL, et al. Accelerated schedule of hepatitis B vaccination in high-risk youth. J Paediatr Child Health 1996; 32: 60–2

    PubMed  CAS  Google Scholar 

  50. Hammond GW, Parker J, Mimms L, et al. Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines. Vaccine 1991 Feb; 9: 97–100

    PubMed  CAS  Google Scholar 

  51. Rustgi VK, Schleupner CJ, Krause DS. Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults. Vaccine 1995; 13(17): 1665–8

    PubMed  CAS  Google Scholar 

  52. Treadwell TL, Keeffe EB, Lake J, et al. Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am J Med 1993 Dec; 95: 584–8

    PubMed  CAS  Google Scholar 

  53. Just M, Berger R, Just V Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults. Postgrad Med J 1987; 63Suppl. 2: 121–3

    PubMed  Google Scholar 

  54. Bryan JP, Craig PG, Reyes L, et al. Randomized comparison of 5 and 10 μg doses of two recombinant hepatitis B vaccines. Vaccine 1995; 13(11): 978–82

    PubMed  CAS  Google Scholar 

  55. Greenberg DP, Vadheim CM, Wong VK, et al. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. Pediatr Infect Dis J 1996; 15(7): 590–6

    PubMed  CAS  Google Scholar 

  56. Panda SK, Ramesh R, Rao KVS, et al. Comparative evaluation of the immunogenicity of yeast-derived (recombinant) and plasma-derived hepatitis B vaccine in infants. J Med Virol 1991; 35(4): 297–302

    PubMed  CAS  Google Scholar 

  57. Leroux-Roels G, Desombere I, Cobbaut L, et al. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines. Vaccine 1997; 15(16): 1732–6

    PubMed  CAS  Google Scholar 

  58. Yap I, Guan R, Chan SH. Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines. J Gastroenterol Hepatol 1995; 10(1): 51–5

    PubMed  CAS  Google Scholar 

  59. Raz R, Dagan R, Gallil A, et al. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens in children. Vaccine 1996; 14(3): 207–11

    PubMed  CAS  Google Scholar 

  60. Yerushalmi B, Raz R, Blondheim O, et al. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens in neonates. Pediatr Infect Dis J 1997; 16(6): 587–92

    PubMed  CAS  Google Scholar 

  61. Arístegui J, Muñiz J, Legorburu AP, et al. Newborn universal immunisation against hepatitis B: immunogenicity and reactogenicity of simultaneous administration of diphtheria/tetanus/pertussis (DTP) and oral polio vaccines with hepatitis B vaccine at 0, 2 and 6 months of age. Vaccine 1995; 13(11): 973–7

    PubMed  Google Scholar 

  62. Giammanco G, Li Volti S, Mauro L, et al. Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccine in infancy. Vaccine 1991 Oct; 9: 747–50

    PubMed  CAS  Google Scholar 

  63. Da Villa G, Picciotto L, Ribera G, et al. Effective antibody response in newborn babies living in Maldives to simultaneous vaccination against hepatitis B, poliomyelitis, diphtheria and tetanus. Vaccine 1995; 13(9): 795–8

    PubMed  Google Scholar 

  64. Li Volti S, Giammanco-Bilancia G, Giammanco G, et al. Duration of hepatitis B antibody response in children immunised with hepatitis B and compulsory vaccines. Eur J Epidemiol 1995; 11(2): 217–9

    Google Scholar 

  65. Blatter M, Reisinger K, Pichichero M, et al. Immunogenicity of diphtheria-tetanus-acellular pertussis (DT-tricomponent Pa), hepatitis B (HB) and Haemophilus influenzae type b (Hib) vaccines administered concomitantly at separate sites along with oral poliovirus vaccine (OPV) in infants [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 1996 Sep 15–18; New Orleans, Louisiana; 161

  66. Mittal SK, Rao S, Kumari S, et al. Simultaneous administration of hepatitis B vaccine with other E.P.I. vaccines. Indian J Pediatr 1994; 61: 183–8

    PubMed  CAS  Google Scholar 

  67. Honorati MC, Mariani E, Dolzani P, et al. Biological parameters influencing the immunological response to plasma derived and recombinant hepatitis B vaccines. Ann Ist Super Sanita 1996; 32(3): 369–74

    PubMed  CAS  Google Scholar 

  68. Da Villa G, Peluso F, Picciotto L, et al. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years. Vaccine 1996; 14(16): 1503–5

    Google Scholar 

  69. Goilav C, Piot P. Vaccination against hepatitis B in homosexual men. A review. Am J Med 1989 Sep 4; 87Suppl. 3A: 21S–5S

    PubMed  CAS  Google Scholar 

  70. Gesemann M, Scheiermann N. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 1995; 13(5): 443–7

    PubMed  CAS  Google Scholar 

  71. Gonzalez ML, Gonzalez JB, Salva F, et al. A 7-year follow-up of newborns vaccinated against hepatitis B. Vaccine 1993; 11(10): 1033–6

    PubMed  CAS  Google Scholar 

  72. Trivello R, Chiaramonte M, Ngatchu T, et al. Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine. Vaccine 1995; 13(2): 139–41

    PubMed  CAS  Google Scholar 

  73. Ramon JM, Bou R, Oromi J. Low-dose intramuscular revaccination against hepatitis B. Vaccine 1996; 14(17/18): 1647–50

    PubMed  CAS  Google Scholar 

  74. Westmoreland D, Player V, Heap DC, et al. Immunization against hepatitis B — what can we expect? Results of a survey of antibody response to immunization in persons ‘at risk’ of occupational exposure to hepatitis B. Epidemiol Infect 1990; 104(3): 499–509

    PubMed  CAS  Google Scholar 

  75. Wood RC, MacDonald KL, White KE, et al. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA1993 Dec; 270(24): 2935–9

    PubMed  CAS  Google Scholar 

  76. Laukamm-Josten U, von Laer G, Feldmeier H, et al. Active immunization against hepatitis B: immunogenicity of a recombinant DNA vaccine in females, heterosexual and homosexual males. Postgrad Med J 1987; 63Suppl. 2: 143–6

    PubMed  Google Scholar 

  77. Winter AP, Follett EAC, McIntyre J, et al. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine 1994; 12(9): 771–2

    PubMed  CAS  Google Scholar 

  78. Fang JWS, Lai CL, Chung HT, et al. Female children respond to recombinant hepatitis B vaccine with a higher titre than male. J Trop Pediatr 1994; 40(2): 104–7

    PubMed  CAS  Google Scholar 

  79. Keet IPM, van-Doorum G, Safary A, et al. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS 1992; 6(5): 59–10

    Google Scholar 

  80. Bruguera M, Cremades M, Salinas R, et al. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol 1992; 14(1): 27–30

    PubMed  CAS  Google Scholar 

  81. Hess G, Rossol S, Voth R, et al. Active immunization of homosexual men using a recombinant hepatitis B vaccine. J Med Virol 1989; 29: 229–31

    PubMed  CAS  Google Scholar 

  82. Zuin G, Principi N, Tornaghi R, et al. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine 1992; 10(12): 857–60

    PubMed  CAS  Google Scholar 

  83. Arrazola MP, de Juanes JR, Ramos JT, et al. Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. J Med Virol 1995; 45(3): 339–41

    PubMed  CAS  Google Scholar 

  84. Polychronopoulou-Androulakaki S, Panagiotou JP, Kostaridou S, et al. Immune response of immunocompromised children with malignancies to a recombinant hepatitis B vaccine. Pediatr Hematol Oncol 1996; 13: 425–31

    PubMed  CAS  Google Scholar 

  85. Rokicka-Milewska R, Jackowska T, Sopylo B, et al. Active immunization of children with leukemias and lymphomas against infection by hepatitis B virus. Acta Paediatr Jpn 1993; 35: 400–3

    PubMed  CAS  Google Scholar 

  86. Grzesiowski P, Sieniawska M. Efficacy of recombinant hepatitis B vaccine in children with chronic renal failure [abstract]. Pediatr Nephrol 1994 Oct; 8(5): C43

    Google Scholar 

  87. Mauri JM, Vallès M, Collaborative Group of Girona. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Nephrol Dial Transplant 1997; 12(4): 729–32

    PubMed  CAS  Google Scholar 

  88. Sennesael JJ, Van der Niepen P, Verbeelen DL. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991; 40(1): 121–8

    PubMed  CAS  Google Scholar 

  89. Quiroga JA, Castillo I, Porres JC, et al. Recombinant γ-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 1990; 12(4): 661–3

    PubMed  CAS  Google Scholar 

  90. Dentico P, Buongiorno R, Volpe A, et al. Long term immunogenicity and protective efficacy of recombinant DNA yeast-derived vaccine in hemodialysis patients. J Nephrol 1993; 6(2): 95–7

    Google Scholar 

  91. El-Reshaid K, Al-Mufti S, Johny KV, et al. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. Vaccine 1994; 12(3): 223–8

    PubMed  CAS  Google Scholar 

  92. Sokal EM, Ulla L, Otte JB. Hepatitis B vaccine response before and after transplantation in 55 extrahepatic biliary atresia children. Dig Dis Sci 1992 Aug; 37(8): 1250–2

    PubMed  CAS  Google Scholar 

  93. Van Thiel DH, Gavaler JS. Response to HBV vaccination in patients with severe liver disease: absence of an HLA effect. Dig Dis Sci 1992; 37(9): 1447–51

    PubMed  Google Scholar 

  94. Smart HL, Van Hegan RJ, Triger DR. Impaired response to recombinant DNA hepatitis B vaccine in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 1991; 3: 299–303

    Google Scholar 

  95. Loinaz C, Ramón de Juanes J, Gonzalez EM, et al. Hepatitis B vaccination results in 140 liver transplant recipients. Hepato Gastroenterology 1997; 44(13): 235–8

    PubMed  CAS  Google Scholar 

  96. Bruguera M, Rodicio JL, Alcazar JM, et al. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990; 8 Suppl.: S47–9

    PubMed  Google Scholar 

  97. Bouter KP, Diepersloot RJA, Wismans PJ, et al. Humoral immune response to a yeast-derived hepatitis B vaccine in patients with type I diabetes mellitus. Diabetic Med 1992; 9: 66–9

    PubMed  CAS  Google Scholar 

  98. Wismans PJ, van Hattum J, de Gast KP, et al. A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls. J Med Virol 1991; 35: 216–22

    PubMed  CAS  Google Scholar 

  99. Åhman L, Bäck E, Bensch K, et al. Non-efficacy of low-dose intradermal vaccination against hepatitis B in Down’s syndrome. Scand J Infect Dis 1993; 25: 16–23

    PubMed  Google Scholar 

  100. Van Damme P, Vranckx R, Meheus A. Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down’s syndrome. Vaccine 1990; 8 Suppl.: S53–5

    Google Scholar 

  101. Rodrigo JM, Serra MA, Aparisi L, et al. Immune response to hepatitis B vaccine in parenteral drug abusers. Vaccine 1992; 10(11): 798–801

    PubMed  CAS  Google Scholar 

  102. Rumi M, Colombo M, Romeo R, et al. Suboptimal response to hepatitis B vaccine in drug users. Arch Intern Med 1991 Mar; 151: 574–8

    PubMed  CAS  Google Scholar 

  103. Lugoboni F, Migliozzi S, Schiesari F, et al. Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users. Vaccine 1997; 15(9): 1014–6

    PubMed  CAS  Google Scholar 

  104. Louagie H, Delanghe J, Desombere I, et al. Haptoglobin polymorphism and the immune response after hepatitis B vaccination. Vaccine 1993; 11(12): 1188–90

    PubMed  CAS  Google Scholar 

  105. Zuckerman JN. Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production. J Med Virol 1996 Dec; 50(4): 283–8

    PubMed  CAS  Google Scholar 

  106. Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA-genes are involved. Tissue Antigens In press; 51

  107. Cheng KF, Chang MH, Lee CY, et al. Response to supplementary vaccination with recombinant or plasma hepatitis B vaccine in healthy non-responding children. Vaccine 1994; 12(10): 899–902

    PubMed  CAS  Google Scholar 

  108. Goldwater PN. Randomized, comparative trial of 20 μg vs 40 μg Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997; 15(4): 353–6

    PubMed  CAS  Google Scholar 

  109. Clemens R, Sänger R, Kruppenbacher J, et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule — results of a post-marketing surveillance. Vaccine 1997; 15(4): 349–52

    PubMed  CAS  Google Scholar 

  110. Chiaramonte M, Ngatchu T, Majori S, et al. Response to an extra dose of hepatitis B vaccine and specific antibody persistence in non-responders to primary immunization. Scand J Gastroenterol 1995; 30(6): 601–3

    PubMed  CAS  Google Scholar 

  111. Palmovic D, Crnjakovic-Palmovic J. Prevention of hepatitis B virus (HBV) infection in health-care workers after accidental exposure: a comparison of two prophylactic schedules. Infection 1993; 21(1): 42–5

    PubMed  CAS  Google Scholar 

  112. Holliday SM, Faulds D. Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection. Pharmacoeconomics 1994 Feb; 5: 141–71

    PubMed  CAS  Google Scholar 

  113. Antoñanzas F, Garuz R, Rovira J, et al. Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain. Pharmacoeconomics 1995; 7(5): 428–43

    PubMed  Google Scholar 

  114. André FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990; 8 Suppl.: S74–8

    PubMed  Google Scholar 

  115. Possible neurological side effects of hepatitis B vaccination? Presc Int 1997; 6 (28): 57–8

    Google Scholar 

  116. Expanded programme on Immunization (EPI): lack of evidence that hepatitis B vaccine causes multiple sclerosis. Weekly Epidemiological Record 1997 May 23; 72 (21): 149–52

  117. Hepatitis B vaccine: What you may have heard and what you should know (fact sheet). Hepatitis Branch, National Center for Infectious Diseases; National Immunization Program; Centers for Disease Control and Prevention (CDC); 1998 Apr 30

  118. Biasi D, De Sandre G, Bambara LM, et al. A new case of reactive arthritis after hepatitis B vaccination [letter]. Clin Exp Rheumatol 1993; 11: 215–20

    PubMed  CAS  Google Scholar 

  119. Pope J, Bell DA, Stevens A. An epidemic of rheumatoid arthritis linked to hepatitis B vacination [abstract]. Arthritis Rheum 1995; 38Suppl. 9: S287

    Google Scholar 

  120. Vautier G, Carty JE. Acute sero-positive rheumatoid arthritis occurring after hepatitis vaccination [letter]. Br J Rheumatol 1994; 33: 991

    PubMed  CAS  Google Scholar 

  121. Bracci M, Zoppini A. Polyarthritis associated with hepatitis B vaccination [letter]. Br J Rheumatol 1996; 36(2): 300–1

    Google Scholar 

  122. Rogerson SJ, Nye FJ. Hepatitis B vaccine associated with erythema nodosum and polyarthritis [letter]. Br Med J 1990 Aug 11; 301(6747): 345

    CAS  Google Scholar 

  123. Cathébras P, Cartry O, Lafage-Proust M-H, et al. Arthritis, hypercalcemia, and lytic bone lesions after hepatitis B vaccination. J Rheumatol 1996; 23: 558–60

    PubMed  Google Scholar 

  124. Lemaître F, Grasland A, Cordonnier C, et al. Maladie de Still après vaccination contre l’hépatite A et B? [abstract]. Rev Med Intern 1996; 17Suppl. 3: 458S

    Google Scholar 

  125. Martinez E, Domingo P. Evans’s syndrome triggered by recombinant hepatitis B vaccine [letter]. Clin Infect Dis 1992; 15(6): 1051

    PubMed  CAS  Google Scholar 

  126. Poullin P, Gabriel B. Thrombocytopenic purpura after recombinant hepatitis B vaccines [letter]. Lancet 1994 Nov 5; 344: 1293

    PubMed  CAS  Google Scholar 

  127. Tudela P, Marti S, Bonal J. Systemic lupus erythematosus and vaccination against hepatitis B [letter]. Nephron 1992; 62(2): 236

    PubMed  CAS  Google Scholar 

  128. Carmeli Y, Oren R. Hepatitis B vaccine side-effect [letter]. Lancet 1993 Jan 23; 341: 250–1

    PubMed  CAS  Google Scholar 

  129. Lilic D, Ghosh SK. Liver dysfunction and DNA antibodies after hepatitis B vaccination [letter]. Lancet 1994 Nov 5; 344: 1292–3

    PubMed  CAS  Google Scholar 

  130. Germanaud J, Causse X, Trinh DH, et al. A case of severe cytolysis after hepatitis B vaccination [letter]. Am J Med 1995; 98: 595–6

    PubMed  CAS  Google Scholar 

  131. Hudson TJ, Newkirk M, Gervais F, et al. Adverse reaction to the recombinant hepatitis B vaccine. J Allergy Clin Immunol 1991; 88(5): 821–2

    PubMed  CAS  Google Scholar 

  132. Allen MB, Cockwell P, Page RL. Pulmonary and cutaneous vasculitis following hepatitis B vaccination. Thorax 1993; 48: 580–1

    PubMed  CAS  Google Scholar 

  133. Cockwell P, Allen MB, Page R. Vasculitis related to hepatitis B vaccine [letter]. Br Med J 1990 Dec 1; 301: 1281

    CAS  Google Scholar 

  134. Di Lernia V, Lo Scocco G, Bisighini G. Erythema multiforme following hepatitis B vaccine [letter]. Pediatr Dermatol 1994; 11(4): 363–4

    PubMed  Google Scholar 

  135. Gisserot O, Carsuzaa F, Marlier S, et al. Lichen plan et vaccination contre l’hepatite B: trois nouvelles observations [abstract]. Rev Med Intern 1996; 17Suppl. 3: 497S

    Google Scholar 

  136. Saywell CA, Wittal RA, Kossard S. Lichenoid reaction to hepatitis B vaccination [case report]. Australas J Dermatol 1997; 38: 152–4

    PubMed  CAS  Google Scholar 

  137. Drucker Y, Prayson RA, Bagg A, et al. Lymphocytic vasculitis presenting as diffuse subcutaneous edema after hepatitis B virus vaccine. J Clin Rheumatol 1997 Jun; 3(3): 158–61

    PubMed  Google Scholar 

  138. Reutens DC, Dunne JW, Leather H. Neuralgic amyotrophy following recombinant DNA hepatitis B vaccination. Muscle Nerve 1990 May: 461

  139. Manna R, De Santis A, Oliviero A, et al. Leucoencephalitis after recombinant hepatitis B vaccine [letter]. J Hepatol 1996; 24: 764–5

    PubMed  CAS  Google Scholar 

  140. Davanipour Z, Stewart CE, McGann DG. Hepatitis B vaccination and asymmetric tinnitus and hearing loss [abstract]. Clin Res 1994; 42(2): 341A

    Google Scholar 

  141. Pirmohamed M, Winstanley P. Hepatitis B vaccine and neurotoxicity. Postgrad Med J 1997; 73: 462–3

    PubMed  CAS  Google Scholar 

  142. Hartman S. Convulsion associated with fever following hepatitis B vaccination [letter]. J Paediatr Child Health 1990; 26: 65

    PubMed  CAS  Google Scholar 

  143. Deisenhammer F, Pohl P, Bösch S, et al. Acute cerebellar ataxia after immunisation with recombinant hepatitis B vaccine. Acta Neurol Scand 1994; 89(6): 462–3

    PubMed  CAS  Google Scholar 

  144. Nadler JP. Multiple sclerosis and hepatitis B vaccination [letter]. Clin Infect Dis 1993; 17(5): 928–9

    PubMed  CAS  Google Scholar 

  145. Brézin AP, Massin-Korobelnik P, Boudin M, et al. Acute posterior multifocal placoid pigment epitheliopathy after hepatitis B vaccine. Arch Ophthalmol 1995; 113(3): 297–300

    PubMed  Google Scholar 

  146. Brézin AP, Lautier-Frau M, Hamedani M, et al. Visual loss and eosinophilia after recombinant hepatitis B vaccine. Lancet 1993 Aug 28; 342: 563–4

    PubMed  Google Scholar 

  147. Noel I, Galloway A, Ive FA. Hypersensitivity to thiomersal in hepatitis B vaccine [letter]. Lancet 1991 Sep 14; 338: 705

    PubMed  CAS  Google Scholar 

  148. Brightman CAT, Scadding GK, Dumbreck LA, et al. Yeast-derived hepatitis B vaccine and yeast sensitivity [letter]. Lancet 1989 Apr 22: 903

    Google Scholar 

  149. Smithkline Beecham Pharmaceuticals. Engerix B Hepatitis B Vaccine (rby). In: ABPI Compendium of Data Sheets and Summaries of Product Characteristics. London: Datapharm Publications Limited, 1996–97: 1100–1

  150. Vaccin Engerix B® enfant et nourisson 10μg/0,5ml. In: Vidal. 73rd ed. Paris: Minitel professional, 1997: 1732–3

  151. Committee on Infectious Diseases. Update of timing of hepatitis B vaccination for premature infants and for children with lapsed immunization. Pediatrics 1994 Sep; 94(3): 403–4

    Google Scholar 

  152. Bowden S. Hepatitis B: treatment for the 21st century. Antiviral Chem Chemother 1997; 8Suppl. 1: 77–82

    CAS  Google Scholar 

  153. Hepatitis B vaccine: injection. WHO Drug Info 1993; 7 (3): 130–1

  154. Good news on hepatitis B vaccination in Europe. Scrip Mag 1997 Nov 28 (2288): 22–3

  155. Viral hepatitis. Universal HB immunization by 1997: where are we now? Viral Hepatitis Prevention Board; 1998 Jan; Fact Sheet 2

  156. Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. BMJ 1997 Apr 5; 314: 1033–7

    Google Scholar 

  157. Lee P-I, Lee C-Y Practical considerations in converting from plasma-derived to recombinant hepatitis B vaccines. Biodrugs 1998; 10(1): 11–25

    PubMed  Google Scholar 

  158. Steffen R. Risks of hepatitis B for travellers. Vaccine 1990; 8: S31–2

    PubMed  Google Scholar 

  159. Wagstaff AJ, Balfour JA. Combination hepatitis A-hepatitis B vaccine. Biodrugs 1997 Sep; 8(3): 235–9

    PubMed  CAS  Google Scholar 

  160. Kanra G, Ceyhan M, Ecevit Z, et al. Primary vaccination of infants with a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine. Pediatr Infect Dis J 1995 Nov; 14(11): 998–1000

    PubMed  CAS  Google Scholar 

  161. Arístegui J, Garrote E, González A, et al. Immune response to a combined hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine administered to infants at 2, 4 and 6 months of age. Vaccine 1997; 15(1): 7–9

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Julie C. Adkins & Antona J. Wagstaff

Authors
  1. Julie C. Adkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antona J. Wagstaff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie C. Adkins.

Additional information

Engerix B®. Use of a trade name is for product identification purposes only and does not imply endorsement. Other hepatitis B vaccines have been included in this review only when directly compared with Engerix B®

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adkins, J.C., Wagstaff, A.J. Recombinant Hepatitis B Vaccine. BioDrugs 10, 137–158 (1998). https://doi.org/10.2165/00063030-199810020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199810020-00005

Keywords

Search

Navigation